Always up to date.
 

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Ad hoc announcement pursuant to Art. 53 LR

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces...

Read more

Medartis shareholders approve all proposals of the Board of Directors

    Ad hoc announcement pursuant to Art. 53 LR
  • 84.8% of the total share capital was represented at this year's Annual General Meeting
  • All proposals of the Board of Directors were approved with a...
Read more

Medartis acquires Nextremity Solutions Inc.

We are pleased to announce the aquisition of Nextremity Solutions Inc., a Warsaw (US) based orthopedic company which develops and markets for the treatment of bone fractures and deformities.

Read more